<html>

<head>
<meta http-equiv=Content-Type content="text/html; charset=utf-8">
<meta name=Generator content="Microsoft Word 15 (filtered)">
<style>
<!--
 /* Font Definitions */
 @font-face
	{font-family:Wingdings;
	panose-1:5 0 0 0 0 0 0 0 0 0;}
@font-face
	{font-family:"Cambria Math";
	panose-1:2 4 5 3 5 4 6 3 2 4;}
@font-face
	{font-family:Calibri;
	panose-1:2 15 5 2 2 2 4 3 2 4;}
@font-face
	{font-family:"Calibri Light";
	panose-1:2 15 3 2 2 2 4 3 2 4;}
 /* Style Definitions */
 p.MsoNormal, li.MsoNormal, div.MsoNormal
	{margin-top:0cm;
	margin-right:0cm;
	margin-bottom:8.0pt;
	margin-left:0cm;
	line-height:107%;
	font-size:11.0pt;
	font-family:"Calibri",sans-serif;}
h1
	{mso-style-link:"Heading 1 Char";
	margin-top:12.0pt;
	margin-right:0cm;
	margin-bottom:0cm;
	margin-left:0cm;
	line-height:107%;
	page-break-after:avoid;
	font-size:16.0pt;
	font-family:"Calibri Light",sans-serif;
	color:#2F5496;
	font-weight:normal;}
h3
	{mso-style-link:"Heading 3 Char";
	margin-top:2.0pt;
	margin-right:0cm;
	margin-bottom:0cm;
	margin-left:0cm;
	line-height:107%;
	page-break-after:avoid;
	font-size:12.0pt;
	font-family:"Calibri Light",sans-serif;
	color:#1F3763;
	font-weight:normal;}
a:link, span.MsoHyperlink
	{color:#0563C1;
	text-decoration:underline;}
p.MsoListParagraph, li.MsoListParagraph, div.MsoListParagraph
	{margin-top:0cm;
	margin-right:0cm;
	margin-bottom:8.0pt;
	margin-left:36.0pt;
	line-height:107%;
	font-size:11.0pt;
	font-family:"Calibri",sans-serif;}
p.MsoListParagraphCxSpFirst, li.MsoListParagraphCxSpFirst, div.MsoListParagraphCxSpFirst
	{margin-top:0cm;
	margin-right:0cm;
	margin-bottom:0cm;
	margin-left:36.0pt;
	line-height:107%;
	font-size:11.0pt;
	font-family:"Calibri",sans-serif;}
p.MsoListParagraphCxSpMiddle, li.MsoListParagraphCxSpMiddle, div.MsoListParagraphCxSpMiddle
	{margin-top:0cm;
	margin-right:0cm;
	margin-bottom:0cm;
	margin-left:36.0pt;
	line-height:107%;
	font-size:11.0pt;
	font-family:"Calibri",sans-serif;}
p.MsoListParagraphCxSpLast, li.MsoListParagraphCxSpLast, div.MsoListParagraphCxSpLast
	{margin-top:0cm;
	margin-right:0cm;
	margin-bottom:8.0pt;
	margin-left:36.0pt;
	line-height:107%;
	font-size:11.0pt;
	font-family:"Calibri",sans-serif;}
span.Heading1Char
	{mso-style-name:"Heading 1 Char";
	mso-style-link:"Heading 1";
	font-family:"Calibri Light",sans-serif;
	color:#2F5496;}
span.Heading3Char
	{mso-style-name:"Heading 3 Char";
	mso-style-link:"Heading 3";
	font-family:"Calibri Light",sans-serif;
	color:#1F3763;}
.MsoChpDefault
	{font-family:"Calibri",sans-serif;}
.MsoPapDefault
	{margin-bottom:8.0pt;
	line-height:107%;}
@page WordSection1
	{size:595.3pt 841.9pt;
	margin:72.0pt 72.0pt 72.0pt 72.0pt;}
div.WordSection1
	{page:WordSection1;}
 /* List Definitions */
 ol
	{margin-bottom:0cm;}
ul
	{margin-bottom:0cm;}
-->
</style>

</head>

<body lang=EN-AU link="#0563C1" vlink="#954F72" style='word-wrap:break-word'>

<div class=WordSection1>

<h1><span lang=EN-US style='font-size:15.0pt;line-height:107%'>2016A04 Discuss
the potential adverse effects of non-depolarising muscle relaxants.</span></h1>

<p class=MsoNormal style='margin-bottom:0cm'><span lang=EN-US>&nbsp;</span></p>

<h3><span lang=EN-US style='font-size:13.0pt;line-height:107%'>List:</span></h3>

<p class=MsoListParagraphCxSpFirst style='margin-top:0cm;margin-right:0cm;
margin-bottom:0cm;margin-left:22.5pt;text-indent:-13.5pt'><span lang=EN-US
style='font-family:Symbol'>·<span style='font:7.0pt "Times New Roman"'>&nbsp;&nbsp;&nbsp;&nbsp;
</span></span><span lang=EN-US>General adverse effects</span></p>

<p class=MsoListParagraphCxSpMiddle style='margin-top:0cm;margin-right:0cm;
margin-bottom:0cm;margin-left:22.5pt;text-indent:-13.5pt'><span lang=EN-US
style='font-family:Symbol'>·<span style='font:7.0pt "Times New Roman"'>&nbsp;&nbsp;&nbsp;&nbsp;
</span></span><span lang=EN-US>Benzylisoquinolinium specific</span></p>

<p class=MsoListParagraphCxSpLast style='margin-top:0cm;margin-right:0cm;
margin-bottom:0cm;margin-left:22.5pt;text-indent:-13.5pt'><span lang=EN-US
style='font-family:Symbol'>·<span style='font:7.0pt "Times New Roman"'>&nbsp;&nbsp;&nbsp;&nbsp;
</span></span><span lang=EN-US>Aminosteroid specific</span></p>

<p class=MsoNormal style='margin-bottom:0cm'><span lang=EN-US>&nbsp;</span></p>

<h3><span lang=EN-US style='font-size:13.0pt;line-height:107%'>General adverse
effects:</span></h3>

<table class=MsoTableGrid border=1 cellspacing=0 cellpadding=0
 style='border-collapse:collapse;border:none'>
 <tr>
  <td width=126 valign=top style='width:94.25pt;border:solid windowtext 1.0pt;
  padding:0cm 5.4pt 0cm 5.4pt'>
  <p class=MsoNormal style='margin-bottom:0cm;line-height:normal'><span
  lang=EN-US>Unsafe paralysis</span></p>
  </td>
  <td width=507 valign=top style='width:380.25pt;border:solid windowtext 1.0pt;
  border-left:none;padding:0cm 5.4pt 0cm 5.4pt'>
  <p class=MsoListParagraphCxSpFirst style='margin-top:0cm;margin-right:0cm;
  margin-bottom:0cm;margin-left:12.35pt;text-indent:-9.0pt;line-height:normal'><span
  lang=EN-US style='font-family:Symbol'>·<span style='font:7.0pt "Times New Roman"'>&nbsp;&nbsp;
  </span></span><span lang=EN-US>Can’t intubate, can’t oxygenate -&gt; desaturation
  -&gt; death</span></p>
  <p class=MsoListParagraphCxSpLast style='margin-top:0cm;margin-right:0cm;
  margin-bottom:0cm;margin-left:12.35pt;text-indent:-9.0pt;line-height:normal'><span
  lang=EN-US style='font-family:Symbol'>·<span style='font:7.0pt "Times New Roman"'>&nbsp;&nbsp;
  </span></span><span lang=EN-US>Absent airway reflexes -&gt; aspiration</span></p>
  </td>
 </tr>
 <tr>
  <td width=126 valign=top style='width:94.25pt;border:solid windowtext 1.0pt;
  border-top:none;padding:0cm 5.4pt 0cm 5.4pt'>
  <p class=MsoNormal style='margin-bottom:0cm;line-height:normal'><span
  lang=EN-US>Inadequate reversal</span></p>
  </td>
  <td width=507 valign=top style='width:380.25pt;border-top:none;border-left:
  none;border-bottom:solid windowtext 1.0pt;border-right:solid windowtext 1.0pt;
  padding:0cm 5.4pt 0cm 5.4pt'>
  <p class=MsoListParagraphCxSpFirst style='margin-top:0cm;margin-right:0cm;
  margin-bottom:0cm;margin-left:12.35pt;text-indent:-9.0pt;line-height:normal'><span
  lang=EN-US style='font-family:Symbol'>·<span style='font:7.0pt "Times New Roman"'>&nbsp;&nbsp;
  </span></span><span lang=EN-US>Risk: distress, type 2 resp failure,
  aspiration</span></p>
  <p class=MsoListParagraphCxSpMiddle style='margin-top:0cm;margin-right:0cm;
  margin-bottom:0cm;margin-left:12.35pt;text-indent:-9.0pt;line-height:normal'><span
  lang=EN-US style='font-family:Symbol'>·<span style='font:7.0pt "Times New Roman"'>&nbsp;&nbsp;
  </span></span><span lang=EN-US>Risk factors:</span></p>
  <p class=MsoListParagraphCxSpMiddle style='margin-top:0cm;margin-right:0cm;
  margin-bottom:0cm;margin-left:30.6pt;text-indent:-9.0pt;line-height:normal'><span
  lang=EN-US style='font-family:"Courier New"'>o<span style='font:7.0pt "Times New Roman"'>
  </span></span><span lang=EN-US>Physiology: hypothermia -&gt; ↓rate of
  enzymatic degradation</span></p>
  <p class=MsoListParagraphCxSpMiddle style='margin-top:0cm;margin-right:0cm;
  margin-bottom:0cm;margin-left:30.6pt;text-indent:-9.0pt;line-height:normal'><span
  lang=EN-US style='font-family:"Courier New"'>o<span style='font:7.0pt "Times New Roman"'>
  </span></span><span lang=EN-US>Pathology: liver failure (↓metabolism), renal
  failure (accumulation), PChE deficiency for mivacurium</span></p>
  <p class=MsoListParagraphCxSpMiddle style='margin-top:0cm;margin-right:0cm;
  margin-bottom:0cm;margin-left:30.6pt;text-indent:-9.0pt;line-height:normal'><span
  lang=EN-US style='font-family:"Courier New"'>o<span style='font:7.0pt "Times New Roman"'>
  </span></span><span lang=EN-US>Long acting drug e.g. pancuronium 60 mins</span></p>
  <p class=MsoListParagraphCxSpMiddle style='margin-top:0cm;margin-right:0cm;
  margin-bottom:0cm;margin-left:30.6pt;text-indent:-9.0pt;line-height:normal'><span
  lang=EN-US style='font-family:"Courier New"'>o<span style='font:7.0pt "Times New Roman"'>
  </span></span><span lang=EN-US>Active metabolites: e.g. 3-OH pancuronium 50%
  potency and long-lasting</span></p>
  <p class=MsoListParagraphCxSpLast style='margin-top:0cm;margin-right:0cm;
  margin-bottom:0cm;margin-left:30.6pt;text-indent:-9.0pt;line-height:normal'><span
  lang=EN-US style='font-family:"Courier New"'>o<span style='font:7.0pt "Times New Roman"'>
  </span></span><span lang=EN-US>Other drugs: e.g. volatile, calcium channel
  blocker</span></p>
  </td>
 </tr>
 <tr>
  <td width=126 valign=top style='width:94.25pt;border:solid windowtext 1.0pt;
  border-top:none;padding:0cm 5.4pt 0cm 5.4pt'>
  <p class=MsoNormal style='margin-bottom:0cm;line-height:normal'><span
  lang=EN-US>Critical illness myopathy</span></p>
  </td>
  <td width=507 valign=top style='width:380.25pt;border-top:none;border-left:
  none;border-bottom:solid windowtext 1.0pt;border-right:solid windowtext 1.0pt;
  padding:0cm 5.4pt 0cm 5.4pt'>
  <p class=MsoListParagraphCxSpFirst style='margin-top:0cm;margin-right:0cm;
  margin-bottom:0cm;margin-left:12.35pt;text-indent:-9.0pt;line-height:normal'><span
  lang=EN-US style='font-family:Symbol'>·<span style='font:7.0pt "Times New Roman"'>&nbsp;&nbsp;
  </span></span><span lang=EN-US>Prolonged paralysis in ICU -&gt; disuse
  atrophy</span></p>
  <p class=MsoListParagraphCxSpMiddle style='margin-top:0cm;margin-right:0cm;
  margin-bottom:0cm;margin-left:12.35pt;text-indent:-9.0pt;line-height:normal'><span
  lang=EN-US style='font-family:Symbol'>·<span style='font:7.0pt "Times New Roman"'>&nbsp;&nbsp;
  </span></span><span lang=EN-US>Vecuronium and atracurium implicated</span></p>
  <p class=MsoListParagraphCxSpLast style='margin-top:0cm;margin-right:0cm;
  margin-bottom:0cm;margin-left:12.35pt;text-indent:-9.0pt;line-height:normal'><span
  lang=EN-US style='font-family:Symbol'>·<span style='font:7.0pt "Times New Roman"'>&nbsp;&nbsp;
  </span></span><span lang=EN-US>? specific drug effect ? immobility</span></p>
  </td>
 </tr>
</table>

<p class=MsoNormal style='margin-bottom:0cm'><span lang=EN-US>&nbsp;</span></p>

<h3><span lang=EN-US style='font-size:13.0pt;line-height:107%'>Benzylisoquinolinium
adverse effects:</span></h3>

<table class=MsoTableGrid border=1 cellspacing=0 cellpadding=0
 style='border-collapse:collapse;border:none'>
 <tr>
  <td width=126 valign=top style='width:94.25pt;border:solid windowtext 1.0pt;
  padding:0cm 5.4pt 0cm 5.4pt'>
  <p class=MsoNormal style='margin-bottom:0cm;line-height:normal'><span
  lang=EN-US>Histamine release</span></p>
  </td>
  <td width=507 valign=top style='width:380.25pt;border:solid windowtext 1.0pt;
  border-left:none;padding:0cm 5.4pt 0cm 5.4pt'>
  <p class=MsoListParagraphCxSpFirst style='margin-top:0cm;margin-right:0cm;
  margin-bottom:0cm;margin-left:12.35pt;text-indent:-9.0pt;line-height:normal'><span
  lang=EN-US style='font-family:Symbol'>·<span style='font:7.0pt "Times New Roman"'>&nbsp;&nbsp;
  </span></span><span lang=EN-US>Direct effect on mast cells. Not immune
  mediated.</span></p>
  <p class=MsoListParagraphCxSpMiddle style='margin-top:0cm;margin-right:0cm;
  margin-bottom:0cm;margin-left:12.35pt;text-indent:-9.0pt;line-height:normal'><span
  lang=EN-US style='font-family:Symbol'>·<span style='font:7.0pt "Times New Roman"'>&nbsp;&nbsp;
  </span></span><span lang=EN-US>Drugs: d-Tubocurarine &gt; mivacurium,
  atracurium &gt;&gt; cisatracurium</span></p>
  <p class=MsoListParagraphCxSpMiddle style='margin-top:0cm;margin-right:0cm;
  margin-bottom:0cm;margin-left:12.35pt;text-indent:-9.0pt;line-height:normal'><span
  lang=EN-US style='font-family:Symbol'>·<span style='font:7.0pt "Times New Roman"'>&nbsp;&nbsp;
  </span></span><span lang=EN-US>Structure-activity:</span></p>
  <p class=MsoListParagraphCxSpMiddle style='margin-top:0cm;margin-right:0cm;
  margin-bottom:0cm;margin-left:30.6pt;text-indent:-9.0pt;line-height:normal'><span
  lang=EN-US style='font-family:"Courier New"'>o<span style='font:7.0pt "Times New Roman"'>
  </span></span><span lang=EN-US>Cisatracurium: the 1Rcis-1R’cis isomer of
  atracurium</span></p>
  <p class=MsoListParagraphCxSpMiddle style='margin-top:0cm;margin-right:0cm;
  margin-bottom:0cm;margin-left:63.35pt;text-indent:-14.75pt;line-height:normal'><span
  lang=EN-US style='font-family:Wingdings'>§<span style='font:7.0pt "Times New Roman"'>&nbsp;
  </span></span><span lang=EN-US>R: stereochemistry of the
  benzyltetrahydroisoquinoline rings</span></p>
  <p class=MsoListParagraphCxSpMiddle style='margin-top:0cm;margin-right:0cm;
  margin-bottom:0cm;margin-left:63.35pt;text-indent:-14.75pt;line-height:normal'><span
  lang=EN-US style='font-family:Wingdings'>§<span style='font:7.0pt "Times New Roman"'>&nbsp;
  </span></span><span lang=EN-US>Cis: geometry of the bulky methoxy at C1 and
  2-alkylester at N1</span></p>
  <p class=MsoListParagraphCxSpMiddle style='margin-top:0cm;margin-right:0cm;
  margin-bottom:0cm;margin-left:30.6pt;text-indent:-9.0pt;line-height:normal'><span
  lang=EN-US style='font-family:"Courier New"'>o<span style='font:7.0pt "Times New Roman"'>
  </span></span><span lang=EN-US>↑Methoxy groups = ↑potency, ↓histamine release</span></p>
  <p class=MsoListParagraphCxSpMiddle style='margin-top:0cm;margin-right:0cm;
  margin-bottom:0cm;margin-left:63.35pt;text-indent:-14.75pt;line-height:normal'><span
  lang=EN-US style='font-family:Wingdings'>§<span style='font:7.0pt "Times New Roman"'>&nbsp;
  </span></span><span lang=EN-US>e.g. atracurium 8, mivacurium 10, doxacurium
  12</span></p>
  <p class=MsoListParagraphCxSpMiddle style='margin-top:0cm;margin-right:0cm;
  margin-bottom:0cm;margin-left:12.35pt;text-indent:-9.0pt;line-height:normal'><span
  lang=EN-US style='font-family:Symbol'>·<span style='font:7.0pt "Times New Roman"'>&nbsp;&nbsp;
  </span></span><span lang=EN-US>Effects:</span></p>
  <p class=MsoListParagraphCxSpMiddle style='margin-top:0cm;margin-right:0cm;
  margin-bottom:0cm;margin-left:30.6pt;text-indent:-9.0pt;line-height:normal'><span
  lang=EN-US style='font-family:"Courier New"'>o<span style='font:7.0pt "Times New Roman"'>
  </span></span><span lang=EN-US>Degranulation of mast cells</span></p>
  <p class=MsoListParagraphCxSpMiddle style='margin-top:0cm;margin-right:0cm;
  margin-bottom:0cm;margin-left:30.6pt;text-indent:-9.0pt;line-height:normal'><span
  lang=EN-US style='font-family:"Courier New"'>o<span style='font:7.0pt "Times New Roman"'>
  </span></span><span lang=EN-US>Effects via G protein coupled receptors</span></p>
  <p class=MsoListParagraphCxSpMiddle style='margin-top:0cm;margin-right:0cm;
  margin-bottom:0cm;margin-left:30.6pt;text-indent:-9.0pt;line-height:normal'><span
  lang=EN-US style='font-family:"Courier New"'>o<span style='font:7.0pt "Times New Roman"'>
  </span></span><span lang=EN-US>H<sub>1</sub> (G<sub>q</sub>): Vasodilatation,
  capillary leak, ↓mAP; ↓AV node conduction, coronary vasoconstriction,
  bronchoconstriction</span></p>
  <p class=MsoListParagraphCxSpMiddle style='margin-top:0cm;margin-right:0cm;
  margin-bottom:0cm;margin-left:30.6pt;text-indent:-9.0pt;line-height:normal'><span
  lang=EN-US style='font-family:"Courier New"'>o<span style='font:7.0pt "Times New Roman"'>
  </span></span><span lang=EN-US>H<sub>2</sub> (G<sub>s</sub>): ↑contractility,
  ↑chronotropy, coronary vasodilatation, bronchodilation (N.B. H<sub>1</sub>-induced
  bronchoconstriction predominates)</span></p>
  <p class=MsoListParagraphCxSpMiddle style='margin-top:0cm;margin-right:0cm;
  margin-bottom:0cm;margin-left:12.35pt;text-indent:-9.0pt;line-height:normal'><span
  lang=EN-US style='font-family:Symbol'>·<span style='font:7.0pt "Times New Roman"'>&nbsp;&nbsp;
  </span></span><span lang=EN-US>Prevention: antihistamine, slower injection</span></p>
  <p class=MsoListParagraphCxSpLast style='margin-top:0cm;margin-right:0cm;
  margin-bottom:0cm;margin-left:12.35pt;text-indent:-9.0pt;line-height:normal'><span
  lang=EN-US style='font-family:Symbol'>·<span style='font:7.0pt "Times New Roman"'>&nbsp;&nbsp;
  </span></span><span lang=EN-US>↓Severity with repeat doses; depletion of mast
  cells</span></p>
  </td>
 </tr>
 <tr>
  <td width=126 valign=top style='width:94.25pt;border:solid windowtext 1.0pt;
  border-top:none;padding:0cm 5.4pt 0cm 5.4pt'>
  <p class=MsoNormal style='margin-bottom:0cm;line-height:normal'><span
  lang=EN-US>Anaphylaxis</span></p>
  </td>
  <td width=507 valign=top style='width:380.25pt;border-top:none;border-left:
  none;border-bottom:solid windowtext 1.0pt;border-right:solid windowtext 1.0pt;
  padding:0cm 5.4pt 0cm 5.4pt'>
  <p class=MsoListParagraphCxSpFirst style='margin-top:0cm;margin-right:0cm;
  margin-bottom:0cm;margin-left:12.35pt;text-indent:-9.0pt;line-height:normal'><span
  lang=EN-US style='font-family:Symbol'>·<span style='font:7.0pt "Times New Roman"'>&nbsp;&nbsp;
  </span></span><span lang=EN-US>Less common - 1 in 10,000</span></p>
  <p class=MsoListParagraphCxSpLast style='margin-top:0cm;margin-right:0cm;
  margin-bottom:0cm;margin-left:12.35pt;text-indent:-9.0pt;line-height:normal'><span
  lang=EN-US style='font-family:Symbol'>·<span style='font:7.0pt "Times New Roman"'>&nbsp;&nbsp;
  </span></span><span lang=EN-US>See later</span></p>
  </td>
 </tr>
 <tr>
  <td width=126 valign=top style='width:94.25pt;border:solid windowtext 1.0pt;
  border-top:none;padding:0cm 5.4pt 0cm 5.4pt'>
  <p class=MsoNormal style='margin-bottom:0cm;line-height:normal'><span
  lang=EN-US>Autonomic ganglion blockade</span></p>
  </td>
  <td width=507 valign=top style='width:380.25pt;border-top:none;border-left:
  none;border-bottom:solid windowtext 1.0pt;border-right:solid windowtext 1.0pt;
  padding:0cm 5.4pt 0cm 5.4pt'>
  <p class=MsoListParagraphCxSpFirst style='margin-top:0cm;margin-right:0cm;
  margin-bottom:0cm;margin-left:12.35pt;text-indent:-9.0pt;line-height:normal'><span
  lang=EN-US style='font-family:Symbol'>·<span style='font:7.0pt "Times New Roman"'>&nbsp;&nbsp;
  </span></span><span lang=EN-US>Mainly caused by d-tubocurarine</span></p>
  <p class=MsoListParagraphCxSpMiddle style='margin-top:0cm;margin-right:0cm;
  margin-bottom:0cm;margin-left:12.35pt;text-indent:-9.0pt;line-height:normal'><span
  lang=EN-US style='font-family:Symbol'>·<span style='font:7.0pt "Times New Roman"'>&nbsp;&nbsp;
  </span></span><span lang=EN-US>Structure-activity: ↑risk if short interonium
  distance</span></p>
  <p class=MsoListParagraphCxSpLast style='margin-top:0cm;margin-right:0cm;
  margin-bottom:0cm;margin-left:12.35pt;text-indent:-9.0pt;line-height:normal'><span
  lang=EN-US style='font-family:Symbol'>·<span style='font:7.0pt "Times New Roman"'>&nbsp;&nbsp;
  </span></span><span lang=EN-US>Effects: ↓HR, ↓mAP (i.e. no baroreceptor
  response)</span></p>
  </td>
 </tr>
 <tr>
  <td width=126 valign=top style='width:94.25pt;border:solid windowtext 1.0pt;
  border-top:none;padding:0cm 5.4pt 0cm 5.4pt'>
  <p class=MsoNormal style='margin-bottom:0cm;line-height:normal'><span
  lang=EN-US>Prolonged apnoea (mivacurium only)</span></p>
  </td>
  <td width=507 valign=top style='width:380.25pt;border-top:none;border-left:
  none;border-bottom:solid windowtext 1.0pt;border-right:solid windowtext 1.0pt;
  padding:0cm 5.4pt 0cm 5.4pt'>
  <p class=MsoListParagraphCxSpFirst style='margin-top:0cm;margin-right:0cm;
  margin-bottom:0cm;margin-left:12.35pt;text-indent:-9.0pt;line-height:normal'><span
  lang=EN-US style='font-family:Symbol'>·<span style='font:7.0pt "Times New Roman"'>&nbsp;&nbsp;
  </span></span><span lang=EN-US>Cis-trans and trans-trans isomers metabolised
  by plasma cholinesterase</span></p>
  <p class=MsoListParagraphCxSpMiddle style='margin-top:0cm;margin-right:0cm;
  margin-bottom:0cm;margin-left:12.35pt;text-indent:-9.0pt;line-height:normal'><span
  lang=EN-US style='font-family:Symbol'>·<span style='font:7.0pt "Times New Roman"'>&nbsp;&nbsp;
  </span></span><span lang=EN-US>Two alleles. Variations: normal,
  dibucaine-resistant, fluoride-resistant, silent</span></p>
  <p class=MsoListParagraphCxSpLast style='margin-top:0cm;margin-right:0cm;
  margin-bottom:0cm;margin-left:12.35pt;text-indent:-9.0pt;line-height:normal'><span
  lang=EN-US style='font-family:Symbol'>·<span style='font:7.0pt "Times New Roman"'>&nbsp;&nbsp;
  </span></span><span lang=EN-US>Rx prolonged apnoea: sedate + ventilate in ICU
  +/- FFP +/- dialysis</span></p>
  </td>
 </tr>
 <tr>
  <td width=126 valign=top style='width:94.25pt;border:solid windowtext 1.0pt;
  border-top:none;padding:0cm 5.4pt 0cm 5.4pt'>
  <p class=MsoNormal style='margin-bottom:0cm;line-height:normal'><span
  lang=EN-US>Laudanosine toxicity</span></p>
  </td>
  <td width=507 valign=top style='width:380.25pt;border-top:none;border-left:
  none;border-bottom:solid windowtext 1.0pt;border-right:solid windowtext 1.0pt;
  padding:0cm 5.4pt 0cm 5.4pt'>
  <p class=MsoListParagraphCxSpFirst style='margin-top:0cm;margin-right:0cm;
  margin-bottom:0cm;margin-left:12.35pt;text-indent:-9.0pt;line-height:normal'><span
  lang=EN-US style='font-family:Symbol'>·<span style='font:7.0pt "Times New Roman"'>&nbsp;&nbsp;
  </span></span><span lang=EN-US>Ester hydrolysis and Hofmann degradation
  product of atracurium and cisatracurium metabolism</span></p>
  <p class=MsoListParagraphCxSpMiddle style='margin-top:0cm;margin-right:0cm;
  margin-bottom:0cm;margin-left:12.35pt;text-indent:-9.0pt;line-height:normal'><span
  lang=EN-US style='font-family:Symbol'>·<span style='font:7.0pt "Times New Roman"'>&nbsp;&nbsp;
  </span></span><span lang=EN-US>Neurotoxic in animals -&gt; seizure</span></p>
  <p class=MsoListParagraphCxSpLast style='margin-top:0cm;margin-right:0cm;
  margin-bottom:0cm;margin-left:12.35pt;text-indent:-9.0pt;line-height:normal'><span
  lang=EN-US style='font-family:Symbol'>·<span style='font:7.0pt "Times New Roman"'>&nbsp;&nbsp;
  </span></span><span lang=EN-US>Tiny concentration in man</span></p>
  </td>
 </tr>
</table>

<p class=MsoNormal style='margin-bottom:0cm'><span lang=EN-US>&nbsp;</span></p>

<h3><span lang=EN-US style='font-size:13.0pt;line-height:107%'>Aminosteroid
adverse effects:</span></h3>

<table class=MsoTableGrid border=1 cellspacing=0 cellpadding=0
 style='border-collapse:collapse;border:none'>
 <tr>
  <td width=126 valign=top style='width:94.25pt;border:solid windowtext 1.0pt;
  padding:0cm 5.4pt 0cm 5.4pt'>
  <p class=MsoNormal style='margin-bottom:0cm;line-height:normal'><span
  lang=EN-US>Anaphylaxis</span></p>
  </td>
  <td width=507 valign=top style='width:380.25pt;border:solid windowtext 1.0pt;
  border-left:none;padding:0cm 5.4pt 0cm 5.4pt'>
  <p class=MsoListParagraphCxSpFirst style='margin-top:0cm;margin-right:0cm;
  margin-bottom:0cm;margin-left:12.35pt;text-indent:-9.0pt;line-height:normal'><span
  lang=EN-US style='font-family:Symbol'>·<span style='font:7.0pt "Times New Roman"'>&nbsp;&nbsp;
  </span></span><span lang=EN-US>Common, often severe</span></p>
  <p class=MsoListParagraphCxSpMiddle style='margin-top:0cm;margin-right:0cm;
  margin-bottom:0cm;margin-left:12.35pt;text-indent:-9.0pt;line-height:normal'><span
  lang=EN-US style='font-family:Symbol'>·<span style='font:7.0pt "Times New Roman"'>&nbsp;&nbsp;
  </span></span><span lang=EN-US>Rocuronium highest 1 in 2,500 (cf. sux 1 in
  2,000)</span></p>
  <p class=MsoListParagraphCxSpMiddle style='margin-top:0cm;margin-right:0cm;
  margin-bottom:0cm;margin-left:12.35pt;text-indent:-9.0pt;line-height:normal'><span
  lang=EN-US style='font-family:Symbol'>·<span style='font:7.0pt "Times New Roman"'>&nbsp;&nbsp;
  </span></span><span lang=EN-US>Structure-activity:</span></p>
  <p class=MsoListParagraphCxSpMiddle style='margin-top:0cm;margin-right:0cm;
  margin-bottom:0cm;margin-left:30.6pt;text-indent:-9.0pt;line-height:normal'><span
  lang=EN-US style='font-family:"Courier New"'>o<span style='font:7.0pt "Times New Roman"'>
  </span></span><span lang=EN-US>Usually due to quaternary NH<sub>4</sub><sup>+</sup></span></p>
  <p class=MsoListParagraphCxSpMiddle style='margin-top:0cm;margin-right:0cm;
  margin-bottom:0cm;margin-left:30.6pt;text-indent:-9.0pt;line-height:normal'><span
  lang=EN-US style='font-family:"Courier New"'>o<span style='font:7.0pt "Times New Roman"'>
  </span></span><span lang=EN-US>? cross-reaction with pholcodine</span></p>
  <p class=MsoListParagraphCxSpMiddle style='margin-top:0cm;margin-right:0cm;
  margin-bottom:0cm;margin-left:12.35pt;text-indent:-9.0pt;line-height:normal'><span
  lang=EN-US style='font-family:Symbol'>·<span style='font:7.0pt "Times New Roman"'>&nbsp;&nbsp;
  </span></span><span lang=EN-US>Pathophysiology:</span></p>
  <p class=MsoListParagraphCxSpMiddle style='margin-top:0cm;margin-right:0cm;
  margin-bottom:0cm;margin-left:30.6pt;text-indent:-9.0pt;line-height:normal'><span
  lang=EN-US style='font-family:"Courier New"'>o<span style='font:7.0pt "Times New Roman"'>
  </span></span><span lang=EN-US>1<sup>st</sup> exposure: sensitization
  (antigen presented to T cell, stimulates B cell, IgE production, fixation on
  mast cells)</span></p>
  <p class=MsoListParagraphCxSpLast style='margin-top:0cm;margin-right:0cm;
  margin-bottom:0cm;margin-left:30.6pt;text-indent:-9.0pt;line-height:normal'><span
  lang=EN-US style='font-family:"Courier New"'>o<span style='font:7.0pt "Times New Roman"'>
  </span></span><span lang=EN-US>2<sup>nd</sup> exposure: systemic mast cell
  degranulation, angioedema, bronchospasm, vasodilatation/capillary leak</span></p>
  </td>
 </tr>
 <tr>
  <td width=126 valign=top style='width:94.25pt;border:solid windowtext 1.0pt;
  border-top:none;padding:0cm 5.4pt 0cm 5.4pt'>
  <p class=MsoNormal style='margin-bottom:0cm;line-height:normal'><span
  lang=EN-US>Cardiac mAChR effects</span></p>
  </td>
  <td width=507 valign=top style='width:380.25pt;border-top:none;border-left:
  none;border-bottom:solid windowtext 1.0pt;border-right:solid windowtext 1.0pt;
  padding:0cm 5.4pt 0cm 5.4pt'>
  <p class=MsoListParagraphCxSpFirst style='margin-top:0cm;margin-right:0cm;
  margin-bottom:0cm;margin-left:12.35pt;text-indent:-9.0pt;line-height:normal'><span
  lang=EN-US style='font-family:Symbol'>·<span style='font:7.0pt "Times New Roman"'>&nbsp;&nbsp;
  </span></span><span lang=EN-US>Vecuronium: agonist -&gt; ↓HR (rare)</span></p>
  <p class=MsoListParagraphCxSpMiddle style='margin-top:0cm;margin-right:0cm;
  margin-bottom:0cm;margin-left:12.35pt;text-indent:-9.0pt;line-height:normal'><span
  lang=EN-US style='font-family:Symbol'>·<span style='font:7.0pt "Times New Roman"'>&nbsp;&nbsp;
  </span></span><span lang=EN-US>Pancuronium: antagonist -&gt; ↑HR (common)</span></p>
  <p class=MsoListParagraphCxSpLast style='margin-top:0cm;margin-right:0cm;
  margin-bottom:0cm;margin-left:12.35pt;text-indent:-9.0pt;line-height:normal'><span
  lang=EN-US style='font-family:Symbol'>·<span style='font:7.0pt "Times New Roman"'>&nbsp;&nbsp;
  </span></span><span lang=EN-US>Rocuronium: minimal effect</span></p>
  </td>
 </tr>
</table>

<p class=MsoNormal style='margin-bottom:0cm'><span lang=EN-US>&nbsp;</span></p>

<p class=MsoNormal style='margin-bottom:0cm'><span lang=EN-US>&nbsp;</span></p>

<p class=MsoNormal style='margin-bottom:0cm'><span lang=EN-US>Feedback welcome
at </span><span lang=EN-GB><a href="mailto:ketaminenightmares@gmail.com"><span
lang=EN-US>ketaminenightmares@gmail.com</span></a></span></p>

<p class=MsoNormal style='margin-bottom:0cm'><span lang=EN-US>&nbsp;</span></p>

</div>

</body>

</html>
